Visualization-Based Discovery of Vanin-1 Inhibitors for Colitis

Area of Science:

• Biochemistry
• Enzymology
• Medicinal Chemistry

Background:

• Vanin-1 (VNN1) exhibits pantetheinase sulfhydrylase activity, hydrolyzing pantetheine into pantothenic acid and cysteamine.
• The enzymatic activity of VNN1 is implicated in the pathogenesis of various diseases.
• Targeting VNN1 offers a potential therapeutic strategy for disease intervention.

Purpose of the Study:

• To design and synthesize novel VNN1 inhibitors using pyrimidine amide scaffolds.
• To develop sensitive and specific fluorescent and bioluminescent probes for inhibitor screening.
• To evaluate the therapeutic potential of VNN1 inhibitors in a preclinical model of inflammatory bowel disease.

Main Methods:

• Pyrimidine amide derivatives were synthesized as potential VNN1 inhibitors.
• A fluorescent probe (PA-AFC) was developed for in vitro inhibitor screening.
• A bioluminescent probe (PA-AL) was utilized for cellular and in vivo inhibitor evaluation.
• Inhibitor efficacy was assessed in a mouse model of colitis.

Main Results:

• Novel VNN1 inhibitors based on pyrimidine amide structures were successfully synthesized.
• The developed fluorescent and bioluminescent probes provided sensitive, specific, and efficient screening methods.
• The synthesized inhibitors demonstrated efficacy in a mouse colitis model, indicating VNN1's role in IBD.

Conclusions:

• Vanin-1 (VNN1) is a viable therapeutic target for inflammatory bowel disease (IBD).
• The developed probes offer a convenient and accurate platform for screening VNN1 inhibitors.
• This study provides a new therapeutic avenue for IBD treatment by targeting VNN1.